NCT00003531View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 10, 1996

Primary Completion Date

July 18, 2005

Study Completion Date

July 18, 2005

Conditions
Stage IV Pancreatic Cancer
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER